Does TYK2/JAK1 Show Potential in Inflammatory Diseases? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

  • By

  • Andrea Surnit

  • July 6, 2026

  • 3 min

Share

  • 1

    SDC-1801 was well tolerated in a phase 1 trial with 95 healthy participants, showing no mortality or serious adverse events.

  • 2

    The study observed pharmacologic activity, with reductions in IP-10 and high-sensitivity C-reactive protein in multiple-dose cohorts.

  • 3

    Pharmacokinetic analyses indicated peak plasma concentrations occurred 3 to 5 hours post-administration, with a half-life of 15 to 27 hours.

  • 4

    Food intake modestly increased drug exposure, suggesting improved absorption through enhanced solubilization.

  • 5

    The study's limitations include its focus on healthy participants and formulation-related differences affecting dose proportionality.

Original Source(s)

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

  • by Andrea Surnit

  • July 6, 2026

Related Content

Emergency diagnosis may flag poor outcomes beyond cancer

Across 13 noncancer conditions, emergency diagnosis was common and associated with higher 1-year mortality.

FDA approves liquid cevimeline for Sjögren disease

The new oral solution offers an alternative to capsules for adults with dry mouth, including those with swallowing difficulties.

Joint Site May Influence RA Treatment Response

A Swiss registry study found that the wrist and second and third metacarpophalangeal joints consistently resolved more slowly than most other joints following biologic or targeted synthetic therapy.